Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 23, 2003. The report details specific corporate actions regarding share re-purchases executed in accordance with authority granted by shareholders at the Annual General Meeting on May 19, 2003.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to specific share buyback transactions:
- May 21, 2003: Purchased 1,200,000 ordinary shares for cancellation at 1,227.9691p per share.
- May 22, 2003: Purchased 1,200,000 ordinary shares for cancellation at 1,247.3984p per share.
Material Changes
The filing reports a reduction in the company's outstanding share count through the cancellation of 2,400,000 ordinary shares over two consecutive days. No other material changes to operations or financial position are disclosed in this text.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or discussion of unusual items beyond the execution of the authorized share re-purchase program.
Investor Verification Checklist
- Verify the total number of shares authorized for re-purchase at the May 19, 2003 Annual General Meeting to assess remaining capacity.
- Confirm the total cost of the 2,400,000 shares purchased and the impact on cash reserves.
- Review subsequent filings for the final status of the share re-purchase program.